Twist Bioscience (TWST)
NASDAQ: TWST · Biotechnology · South San Francisco, CA
Our rating: Neutral
Call changed from Cautious to Neutral at $112.00, low conviction, November 17, 2026.
Breaks if: The Neutral call turns Cautious if FCF burn widens beyond $130 million on a trailing twelve-month basis in either of the next two annual filings, signaling that cash discipline at this market cap is breaking down. It turns Positive if FCF loss narrows below $30 million on a trailing twelve-month basis within four quarters, putting a credible path to cash-flow breakeven in view. On price, a drawdown of 30 percent or more over the next year without a commensurate negative revision to the fundamental picture would also bring the call under review — that magnitude of de-rating would suggest the market has found a reason to reprice the growth premium that the current filings do not yet reveal.
Key figures
| Market value | $7.0B |
|---|---|
| Revenue, last 12 months | $459M |
| Net income, last 12 months | −$130M |
| Free cash flow, last 12 months | −$89M |
| Price to earnings | n/a |
| Free cash flow yield | −1.3% |
| Dividend yield | 0.0% |
| Operating margin | −30.4% |
| Return on equity | −19.1% |
| Beta to the S&P 500 | 2.17 |
| Volatility, annualized | 73.8% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $127M | 27.9% | $-0.30 | −$20M |
| June 30, 2026 | $118M | 23.2% | $-0.56 | −$9M |
| March 31, 2026 | $111M | 19.3% | $-0.71 | −$25M |
| December 31, 2025 | $104M | 16.9% | $-0.50 | −$35M |
| September 30, 2025 | $99M | 16.9% | $-0.45 | −$24M |
| June 30, 2025 | $96M | 17.9% | $0.33 | −$11M |
| March 31, 2025 | $93M | 23.2% | $-0.66 | −$17M |
| December 31, 2024 | $89M | 24.1% | $-0.53 | −$24M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.13B: Claude 72%, Gemini 88%, Mistral 88%
- Diluted earnings per share are above zero: Claude 8%, Gemini 12%, Mistral 20%
- Free cash flow for the quarter is above zero: Claude 25%, Gemini 8%, Mistral 5%
- Backlog at the end of the quarter is at least $0.02B: Claude 60%, Gemini 93%, Mistral 82%
58 ledger entries and 10 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.